Moya Torrecilla Francisco, Álvarez-Corral Gemma, Gutiérrez Pérez Eva, Morell-Garcia Daniel, Ortega Pérez Juan, Rodríguez Beatriz Miriam, Sánchez Martín Leticia, Temboury Ruiz Francisco
FML Emergency Medicine Department, Quirónsalud Málaga Hospital, 29004 Málaga, Spain.
Sport and Med Clinic, 29640 Málaga, Spain.
J Clin Med. 2025 Jun 10;14(12):4095. doi: 10.3390/jcm14124095.
To evaluate the economic impact associated with the use of specific brain biomarkers glial fibrillary acid protein (GFAP) and ubiquitin C-terminal hydrolase L1 (UCH-L1) in adult patients with suspected mild traumatic brain injury (TBI) in a standard Spanish hospital setting. We used a budget impact analysis (BIA) to compare the cost of standard of care using head computed tomography (CT) to evaluate intracranial injury with a scenario incorporating specific biomarkers GFAP and UCH-L1 in an estimated population of 3500 adult patients attending the hospital emergency department with a score of 13 to 15 on the Glasgow Coma Scale (GCS). The probabilities associated with clinical procedures were obtained from a multidisciplinary group of experts from Spanish hospitals and supplemented with data from the literature. Costs were estimated using hospital tariffs from the Spanish autonomous communities and other official sources. The incorporation of specific biomarkers GFAP and UCH-L1 in the management of mild TBI could generate an estimated annual savings of EUR 696,634 in a standard Spanish hospital, mainly due to reduced CT use. The average savings per patient would be EUR 199.04, and the care time would be reduced by 111 min. Sensitivity analysis, with variations of ±20% in the parameters, confirms these savings. This study suggests that the use of specific biomarkers GFAP and UCH-L1 in the management of mild TBI patients in Spain could reduce the average cost per patient, generating significant savings for hospitals. Future studies that incorporate data from clinical records will help validate these results.
为评估在西班牙一家标准医院环境中，使用特定脑生物标志物胶质纤维酸性蛋白（GFAP）和泛素羧基末端水解酶L1（UCH-L1）对疑似轻度创伤性脑损伤（TBI）成年患者的经济影响。我们采用预算影响分析（BIA），将使用头部计算机断层扫描（CT）评估颅内损伤的标准治疗成本，与在估计3500名格拉斯哥昏迷量表（GCS）评分为13至15分、前往医院急诊科就诊的成年患者群体中纳入特定生物标志物GFAP和UCH-L1的情况进行比较。与临床程序相关的概率来自西班牙医院的多学科专家小组，并辅以文献数据。成本使用西班牙自治区和其他官方来源的医院收费标准进行估算。在西班牙一家标准医院中，在轻度TBI管理中纳入特定生物标志物GFAP和UCH-L1估计每年可节省696,634欧元，主要原因是CT使用减少。每位患者的平均节省金额为199.04欧元，护理时间将减少111分钟。参数变化±20%的敏感性分析证实了这些节省。本研究表明，在西班牙轻度TBI患者管理中使用特定生物标志物GFAP和UCH-L1可降低每位患者的平均成本，为医院节省大量资金。纳入临床记录数据的未来研究将有助于验证这些结果。
